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Previously in this journal, we published a phase 1 study of 
nebulized heparin in patients with acute lung injury [1]. 
Patients were administered heparin at doses of 50,000, 
100,000, 200,000, or 400,000 U/day for 2 days, and 
broncho  alveolar  lavage  (BAL)  ﬂ  uid samples were taken at 
baseline and after the last heparin dose. Th  e study 
demonstrated a trend to reduced coagulation activation 
(prothrombin fragments) in BAL ﬂ  uid after the last dose 
of nebulized heparin [1].
Following publication of these data, we were oﬀ  ered 
the possibility of further analysis of the BAL ﬂ  uid with 
additional markers of coagulation activation, including 
thrombin-antithrombin complexes (TATcs), ﬁ  brin degra-
da  tion products (FDPs), and plasminogen activator 
activity (PAI-1) levels. We wish to publish the results of 
this further analysis. Th  e 400,000 U/day group had one 
patient more than the same group in the previously 
published data.
We found that TATc and FDP levels were signiﬁ  cantly 
reduced in patients treated with 400,000 U/day of 
nebulized heparin, but not PAI-1 (Figure 1 overleaf). We 
believe that these data are important as they demonstrate 
for the ﬁ   rst time that nebulized heparin signiﬁ  cantly 
reduces coagulation activation in the lungs of critically ill 
patients with acute lung injury. Th  is may be important 
knowledge as inﬂ   ammatory mechanisms related to 
coagulation activation, such as hyaline membrane 
formation and microvascular thrombosis, may mediate 
lung injury [2,3].
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© 2010 BioMed Central LtdFigure 1. Changes in markers of coagulation activation in bronchoalveolar fl  uid before and after 2 days of nebulized heparin. Each line 
represents a single patient (*P <0.01, **P <0.001, paired t test). FDP, fi  brin degradation product; NS, not signifi  cant; PAI-1, plasminogen activator 
activity; TATc, thrombin-antithrombin complex.
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